The ROI of Biological Age Testing for Employers: A Framework for Measuring Wellness Programme Value

Biological age testing gives employers a measurable way to track whether wellness programme spending is actually changing employee health, not just employee attendance. It replaces participation metrics, such as gym check-ins or app downloads, with a single biomarker: how fast an employee's immune system is biologically aging compared to their birth certificate age. This article breaks down how HR and benefits leaders can build an ROI framework around biological age testing, starting with a pilot cohort and ending with a data-backed case for renewal. 

For the full science behind the biomarker, see our guide to GlycanAge for Healthcare Providers, Functional Medicine Clinics and Corporate Wellness Programmes. 

What is biological age, and why does it matter for a wellness programme budget?

Biological age measures how fast a person's body is functionally aging, distinct from chronological age, which is simply the years elapsed since birth. Chronological age is fixed: everyone accumulates it at the same rate regardless of health status. Biological age reflects physiological health and functional capacity instead, and it varies significantly between employees of the same chronological age, driven by lifestyle, stress load, and other modifiable factors. This distinction matters to a budget owner because aging is the single biggest risk factor for chronic disease, and it is a workforce's biological age, not its birthdate, that is understood to correlate with future healthcare needs. A benefits team evaluating a wellness spend should ask whether the programme is changing that number, not just whether employees are showing up. 

How does GlycanAge measure whether a wellness intervention is actually working?

GlycanAge measures active, current chronic inflammation through IgG glycosylation: the glycans, or complex sugars, attached to immune antibodies that shift measurably in response to lifestyle change. Because glycans sit at the interface of genetics and environment, they respond to real interventions: diet, exercise, stress reduction, sleep, and medical treatment all move the result. GlycanAge is a modifiable biomarker, responsive to both lifestyle and medical interventions, that reflects biological changes occurring before disease onset and serves as a predictive marker of future health outcomes. For an employer, this means a wellness programme's effect on biology, rather than its effect on attendance sheets, becomes something you can actually put in a report to finance. 

What would a corporate rollout of biological age testing look like in practice?

A corporate rollout starts with a baseline test across the population being tracked, followed by a retest 6 to 12 months later for lifestyle-based programmes, to see whether the programme moved the number. Organizations working with biological age biomarkers have found that measuring accurately and regularly supports personalized recommendations in three ways: establishing a baseline for each participant's current health, revealing where individual intervention is needed rather than applying a one-size-fits-all wellness plan, and tracking progress in a way that sustains participation. For a workforce, this typically means offering the test as part of an executive health benefit or a targeted pilot within a high-value population, with each result paired with expert interpretation so employees understand what their number means and what to do next, rather than a raw report with no context. GlycanAge offers a 1:1 Result Interpretation Call with a longevity specialist that employees can book once their results are ready, which is the layer that turns a number into an action plan.

"We have to have a way to monitor ourselves, to see whether what we are doing is actually helping or harming us."

— Prof. Gordan Lauc, Co-Founder and Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

Should we pilot this with executives first, or roll it out company-wide?

Biological age testing is most immediately useful for populations under sustained occupational stress, because chronic workplace stress is one of the clearest modifiable drivers of accelerated immune aging. Executives and high-performers managing constant workload pressure are a natural starting cohort for any employer piloting biological age testing, since this group typically has the budget allocation and the clearest before-and-after story to tell finance stakeholders. That said, the underlying biology applies to any employee population: sedentary habits, poor sleep, and chronic stress accelerate biological aging regardless of job title, while quality sleep, exercise, and relaxation practices decelerate it. A phased rollout, starting with an executive or high-stress cohort before expanding company-wide, gives HR teams a manageable pilot with a clear cost-benefit case before broader investment.

"I can see clearly that emotional stress can elevate your GlycanAge. It's a signal to reflect on and ask what you can change, because it's impacting your health. The results show me that, and it excites me to act."

— Dr. Nick Engerer, PhD, Founder of A Longer Life 

How often should employees be retested to demonstrate programme impact?

Retesting cadence should match the intervention timeline being evaluated, giving biology enough time to shift while keeping the feedback loop tight enough to inform programme decisions within a single budget cycle. Glycan-based biological age responds within 6 to 12 months for lifestyle-based interventions such as stress management, sleep, and exercise programmes, or 3 to 4 months where the programme includes a pharmaceutical or HRT component, so corporate programmes can build a retesting cadence aligned to those windows into benefits planning without waiting years for a signal. This is also where reviewing individual results against the actions each participant actually took between tests adds value: it lets a wellness provider start distinguishing which interventions are genuinely working for that specific population, rather than relying purely on general literature. For an employer, this turns an annual wellness benefit into a data-backed programme evaluation, not a static perk. 

What should we ask a vendor before adding a biological age biomarker to our benefits programme?

Ask whether the biomarker has been independently reviewed for predictive accuracy and responsiveness to intervention, since these two properties determine whether a biological age result is useful at scale. GlycanAge is designed to respond to both lifestyle and pharmacological interventions, giving a benefits team a signal that reflects real behavioural and clinical change rather than a static risk score. Ask, too, how results are delivered and interpreted: a raw number without clinical context leaves both HR teams and employees unsure what to do next, so a vendor offering structured interpretation alongside the result, not just a spreadsheet of figures, is the one worth including in a benefits package. Confirm the retest cadence the vendor recommends lines up with your budget cycle, so the programme produces a usable signal before the next renewal conversation. 

How do we translate a biological age result into something finance teams understand?

A biological age figure gives immediate, intuitive context that a standard biomarker panel does not: it tells an employee and an employer whether biology looks ten years older or younger than a birth certificate suggests, rather than leaving them to interpret a red, amber, green scale on a cholesterol ratio. For an employer already running annual health screenings, a biological age biomarker is the additional layer that shows whether those screening results are translating into slower biological aging over time. That single number, tracked at baseline and at retest, is what turns a wellness line item into a measurable outcome finance can evaluate alongside healthcare utilisation and absenteeism data.

"I've transferred from prescribing pills to prescribing lifestyle. I measure biological age in all of my clients now as a critical piece of data we should all be mapping to, using that data to drive the decision to change your lifestyle."

— Dr. Alka Patel, GP, Lifestyle Medicine Doctor, Author, and Podcaster

Is this only relevant for large enterprises with big wellness budgets?

No. The biology driving accelerated aging, chronic stress, poor sleep, sedentary behavior, does not discriminate by company size or job title. What differs is the entry point: a phased pilot with a smaller, high-stress cohort, such as a leadership team, gives any organization a manageable, budget-contained way to build a before-and-after case before committing to a full population rollout. The retest cadence and interpretation model scale the same way whether the pilot group is 20 people or 2,000.

Benefits leaders who want to move past participation metrics and build a defensible ROI case for wellness spend can start with a pilot cohort. Visit the Healthcare Providers page to discuss a corporate rollout, or explore partner sign-up to bring GlycanAge into an existing benefits or occupational health programme.

Ready to measure whether your wellness programme is changing employee biology, not just attendance? Start with a pilot cohort and a baseline test. 

Partner With GlycanAge →

External sources

• https://pmc.ncbi.nlm.nih.gov/articles/PMC3818009/ — Moreno-Villanueva M, Morath J, Vanhooren V, Elbert T, Kolassa S, Libert C, Bürkle A, Kolassa IT. N-glycosylation profiling of plasma provides evidence for accelerated physiological aging in post-traumatic stress disorder. Transl Psychiatry. 2013;3(10):e320.